
Here’s a look back at the key highlights, SYNAPSE’s contributions, and the collaborative spirit that will drive PROBE’s mission to transform osteoarthritis (OA) care through data-driven innovation, federated learning, and patient-centric tools.
After the project launch back in December 2025, we shared an outline of the project, its patient-focused approach, main objectives, and future vision.
The kick-off meeting held in Rotterdam marked the first step toward these goals, uniting partners to align on scientific objectives, governance, and collaborative workflows.
SYNAPSE’s Leadership: Driving Communication
As leader of WP6 (Communication and Sustainability), SYNAPSE took centre stage to present our vision for disseminating PROBE’s outputs and engaging stakeholders. Our presentation focused on dissemination and communication strategies, developing a multi-channel approach to reach patients, clinicians, regulators, industry, and researchers in a coherent and effective manner:
"We’re excited to play an important role in this journey with all of the world-leading experts, vital stakeholder specialists, and cutting edge researchers represented in this Consortium and look forward to sharing updates on our progress as PROBE moves forward. Together, we’re not just advancing OA research—we’re redefining how data, technology, and collaboration can improve lives." - Chris James, Project Manager at SYNAPSE
SYNAPSE’s Expertise: Guiding Coordination
Alongside with Erasmus MC, SYNAPSE plays a key role in ensuring the project’s smooth execution, strategic alignment, and operational efficiency. Our contributions include:
SYNAPSE’s experience in managing complex consortia ensures that WP1’s foundational work—coordination, risk management, and compliance—remains robust, setting the stage for PROBE’s success.

Looking ahead: SYNAPSE’s Next Steps in PROBE
The kick-off was just the beginning. Over the coming months SYNAPSE will focus on:
For more information, check PROBE website and follow the project on LinkedIn.

To improve the lives of more than 500 million osteoarthritis patients worldwide, the ambitious and innovative PROBE project brings together 38 partners across academia and industry to harness big data and predictive modelling for enhanced development and design of clinical trials, novel relevant multimodal endpoints, and tools for optimisation of treatment strategies.